. 2017 Aug 8;8(11):337–347. doi: 10.1177/2042098617722516

Table 1.

The characteristics of the four included studies in the analysis.

Study	Treatment regimen	Evaluable patients	Indication	Median age (year) case, control	ECOG-PS (%)		Prior chemotherapy (%) case, control	Duration of anti-CDK 4/6 Treatment median in months
Study	Treatment regimen	Evaluable patients	Indication	Median age (year) case, control	0	1	Prior chemotherapy (%) case, control	Duration of anti-CDK 4/6 Treatment median in months
PALOMA-1, phase II^1,7	Palbociclib + letrozole versus letrozole alone	165 (83 versus 77)	Advanced breast cancer, no prior systemic treatment	63, 64	55, 56	45, 44	40, 46	27.9, 29.6
PALOMA-2, phase III⁸	Palbociclib + letrozole	666 (444 versus 222)	advanced breast cancer, no prior systemic treatment	62, 61	58%, 46%	40%, 53%	n/a	n/a
PALOMA-3, Phase III^9,20	Fulvestrant + palbociclib or placebo	517 (345 versus 172)	endocrine-resistant MBC	57, 56	207 (59.7), 115 (66.1)	140 (40.3), 59 (33.9)	251 (72.3%), 138 (79.3%)	5.6
MONALEESA-2, phase III¹²	Ribociclib + letrozole or placebo + letrozole	668	recurrent or MBC, no prior systemic therapy	62, 63	61.4, 60.5	38.6, 39.5	43.7, 43.4	15.3

ECOG-PS, Eastern Cooperative Oncology Group Performance Status; n/a, not applicable; MBC, Metastatic Breast Cancer.